| 1 | ALE.F02 | - | - | - | - | 1件: 220 220 💬
|
| 2 | Corticosteroids | - | - | - | - | 12件: 41 41, 46, 49, 63, 64, 97, 107, 113, 164, 220, 296, 300 💬
|
| 3 | Cyclophosphamid | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬
| - | - | 2件: 66 66, 220 💬
|
| 4 | Glucocorticoid | - | - | - | - | 6件: 46 46, 49, 66, 113, 220, 228 💬
|
| 5 | Immunosuppressive agents | - | - | - | - | 4件: 13 13, 50, 96, 220 💬
|
| 6 | Methylprednisolone pulse | 1件: Methylprednisolone Methylprednisolone | 2件: Methylprednisolone
Methylprednisolone
,
Methylprednisolone acetate
💬
| 1件: NR3C1 NR3C1 💬
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 66 66, 220 💬
|
| 7 | Pentoxifylline | 1件: Pentoxifylline Pentoxifylline | 1件: Pentoxifylline
Pentoxifylline
💬
| - | - | 11件: 26 26, 56, 84, 93, 96, 97, 113, 220, 222, 296, 298 💬
|
| 8 | Pioglitazone | 1件: Pioglitazone Pioglitazone | 2件: Pioglitazone hydrochloride
Pioglitazone hydrochloride
,
Pioglitazone
💬
| 1件: NR1C3 NR1C3 💬
| 12件: AMPK signaling pathway AMPK signaling pathway, Efferocytosis, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 16件: 2 2, 6, 13, 15, 20, 46, 49, 65, 67, 81, 86, 220, 229, 265, 298, 299 💬
|
| 9 | Rituximab | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬
| 1件: MS4A1 MS4A1 💬
| 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 52件: 11 11, 13, 14, 19, 26, 34, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 172, 220, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 💬
|
